Next Generation
Flow Cytometry Presentations 

26th International Molecular Medicine Tri Conference

Q2 Solutions presented on multiple flow cytometry capabilities at the 26th International Molecular Medicine Tri-Conference in March 2019. The two presentations, part of the “Cellular Phenotyping Assays in Oncology Trials” short course, were given to provide the development, validation and implementation of cellular phenotyping assays, and analysis of results.  They discussed recent developments in flow cytometry systems and practices for immuno-oncology drug development that constitute Next Generation Flow Cytometry, and shared a case study on validating a cellular DNA content assay.

Download these presentations to learn more.

Next Generation Immuno-Oncology Flow Cytometry – Mark Edinger. This presentation provides an overview of new and advanced flow cytometry technologies to expand and enhance the ability to monitor discrete cellular populations in clinical programs, 

Validation of a Flow Cytometry Assay to Assess DNA Content in Cryopreserved PBMCs -Megan McCausland. This presentation summarizes a case study of the development and validation of a cellular DNA-content assay as a proof-of-mechanism, pharmacodynamic biomarker in oncology trials


Mark Edinger, Scientific Advisor, Flow Cytometry
Megan McCausland, Senior Scientist, Translational Science

Related Services:

Global Flow Cytometry Services

Unique global flow cytometry services implemented with customizable solutions are designed to meet your clinical trial needs

Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

The Power of the Central Laboratory for Immuno-Oncology Drug Development

Read More